Aurinia Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Peter Greenleaf
Chief executive officer
US$8.8m
Total compensation
| CEO salary percentage | 9.0% |
| CEO tenure | 5yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.8yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Apr 18Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 17Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Feb 15Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
Jan 28We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price
Dec 18Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement
Jun 11Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher
May 09We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%
Nov 04Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus
Sep 19Aurinia Pharmaceuticals: The Right Play Now
Aug 24Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model
Aug 15Aurinia Pharma Q2 2022 Earnings Preview
Aug 03Aurinia lupus nephritis drug recommended in Europe
Jul 22A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)
Jul 04Aurinia: Redemption On Lupkynis Sales And Possible EMA Approval
May 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$78m |
| Sep 30 2023 | n/a | n/a | -US$77m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$97m |
| Dec 31 2022 | US$9m | US$791k | -US$108m |
| Sep 30 2022 | n/a | n/a | -US$115m |
| Jun 30 2022 | n/a | n/a | -US$157m |
| Mar 31 2022 | n/a | n/a | -US$168m |
| Dec 31 2021 | US$1m | US$724k | -US$181m |
| Sep 30 2021 | n/a | n/a | -US$156m |
| Jun 30 2021 | n/a | n/a | -US$148m |
| Mar 31 2021 | n/a | n/a | -US$127m |
| Dec 31 2020 | US$11m | US$673k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$129m |
| Jun 30 2020 | n/a | n/a | -US$110m |
| Mar 31 2020 | n/a | n/a | -US$102m |
| Dec 31 2019 | US$5m | US$438k | -US$88m |
Compensation vs Market: Peter's total compensation ($USD8.84M) is above average for companies of similar size in the US market ($USD3.44M).
Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.
CEO
Peter Greenleaf (53 yo)
5yrs
Tenure
US$8,837,397
Compensation
Mr. Peter S. Greenleaf, M.B.A., is Director at NVN Liquidation Inc. He serves as Director at ValenzaBio, Inc. since August 2022. He has been President, Chief Executive Officer and Director of Aurinia Pharm...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5yrs | US$8.84m | 0.22% $ 1.5m | |
| Chief Financial Officer | 4yrs | US$3.29m | 0.078% $ 546.1k | |
| Executive Vice President of Operations & Strategy | no data | US$3.31m | 0.11% $ 740.0k | |
| Executive VP | 3.4yrs | US$3.24m | 0.054% $ 381.6k | |
| Executive Vice President of Research & Development | 1.8yrs | US$3.24m | no data | |
| Head of the Corporate Communications & Investor Relations | no data | no data | no data | |
| Vice President of Sales | 4.2yrs | no data | no data | |
| Chief Business Officer | 3.8yrs | US$702.00k | 0% $ 0 | |
| Senior Vice President of Global Regulatory Affairs | no data | no data | no data | |
| Chief Commercial Officer | 1.8yrs | no data | 0.051% $ 360.0k | |
| Vice President of Investor Relation | no data | no data | no data |
3.8yrs
Average Tenure
53yo
Average Age
Experienced Management: AUPH's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5yrs | US$8.84m | 0.22% $ 1.5m | |
| Director | less than a year | US$1.10m | no data | |
| Independent Director | 4.8yrs | US$262.37k | 0.010% $ 72.6k | |
| Independent Director | 4.4yrs | US$264.87k | 0.0064% $ 44.9k | |
| Director | less than a year | no data | no data | |
| Chairman | 5yrs | US$244.87k | 0.023% $ 162.6k | |
| Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 8.9yrs | US$262.37k | 0.028% $ 194.8k | |
| Independent Director | 2.8yrs | US$256.49k | 0.012% $ 87.9k |
4.4yrs
Average Tenure
65yo
Average Age
Experienced Board: AUPH's board of directors are considered experienced (4.4 years average tenure).